

1 **Supporting Information**

2 **Breaking the Heavy-Atom Paradigm: Weak-Donor-Engineered Triplet**
3 **Harvesting in BODIPY Photosensitizers for Immunogenic Pyroptosis Therapy**

4 Hyeong Seok Kim,^{1,2+} Hyeonji Rha,¹⁺ Mohammad Izadyar,^{3,5+} Supphachok Chanmungkalakul,³ Haiqiao Huang,⁴ Yi
5 Young Kang,² Jae-Won Ka,² Yunjie Xu,^{1*} Mingle Li,^{4*} Xiaogang Liu,^{3*} and Jong Seung Kim^{1*}

6
7 **Affiliations**

8 ¹ Department of Chemistry, Korea University, Seoul, 02841, Korea

9 ² Advanced Functional Polymers Research Center, Korea Research Institute of Chemical Technology, Daejeon, 34114,
10 Korea.

11 ³ Fluorescence Research Group, Singapore University of Technology and Design, 487372, Singapore

12 ⁴ College of Materials Science and Engineering, Shenzhen University, Shenzhen, 518060, China

13 ⁵ Research Center for Modeling and Computational Sciences, Faculty of Science, Ferdowsi University of Mashhad,
14 Mashhad 9177948974, Iran

15
16 ⁺ These authors contribute equally to this work.

17 ^{*} Authors to whom correspondence should be addressed.

18 Prof. Jong Seung Kim, E-mail: jongskim@korea.ac.kr

19 Prof. Xiaogang Liu, E-mail: xiaogang_liu@sutd.edu.sg

20 Prof. Mingle Li, E-mail: limingle@szu.edu.cn

21 Dr. Yunjie Xu, E-mail: xuyunjie87@korea.ac.k

22

23 **This file includes**

24 1. Materials and Instruments

25 1.1 Materials

26 1.2 Instruments

27 2. Synthesis of thiophene-bridged heavy-atom-free BODIPY photosensitizers (PSs)

28 2.1 Overall synthetic schemes

29 2.2 Detailed synthetic procedures

30 2.2.1. Synthesis of donor-thiophene units (TPA-th, DP-Bth, and Cbz-Bth)

31 2.2.2. Synthesis of thiophene-bridged BODIPY PSs

32 Supporting Figures: Fig. S1 to S17

33 3. Additional experimental details and methods

34 Supporting Figures: Fig. S18 to S37

35 4. Reference

36 1. Materials and Instruments

37 1.1. Materials

38 Materials and Instruments for Chemical Synthesis and Characterization


39 β -Nicotinamide adenine dinucleotide reduced disodium salt hydrate (NADH, CAS No. 606-68-8) was
40 purchased from Sigma Aldrich. 5-Bromobenzothiophene (98%, CAS No. 4923-87-9) and sodium *tert*-
41 butoxide (97%, CAS No. 865-48-5), tris(dibenzylideneacetone)dipalladium, (97%, CAS No. 51364-
42 51-3), anhydrous toluene (99.8%, CAS No. 108-88-3, packaged under Argon), *N*-iodosuccinimide
43 (97%, CAS No. 516-12-1), 1,3-dibenzofuran (97%, CAS No. 5471-63-6), trimethyl borate, (99%, CAS
44 No. 121-43-7), and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone(CAS No. 84-58-2) were purchased
45 from Alfa Aesar. 2,4-Dimethylpyrrole (CAS No. 625-82-1) was purchased from carbosynth. 2-
46 Bromothiophene (98%, CAS No. 1003-09-4), 4-bromotriphenylamine (97%, CAS No. 35809-26-4),
47 potassium carbonate (CAS No. 584-08-7), and trifluoroacetic acid (CAS No. 76-05-1) were purchased
48 from TCI (Tokyo Chemical Industry). Tetrakis(triphenylphosphine)palladium(0) (CAS No. 14221-01-
49 3) was purchased from SY Innovation. The calcein-AM/PI Double Stain Kit was obtained from
50 Invitrogen. The cellular NAD/NADH assay kit (colorimetric) was purchased from Promega (catalog
51 nos. G9071). The FITC annexin V detection kit was purchased from BD Pharmingen™ (Cat No.
52 556547). The nuclear imaging agent Hoechst 33342 was purchased from Invitrogen (Cat No. H3570).
53 9,10- anthracenediyl-bis(methylene) dimalononic acid (CAS No. 307554-62-7), the superoxide assay kit
54 (dihydrorhodamine 123, DHR123) for superoxide radical ($O_2^{\cdot-}$) detection, 2'-7'dichlorofluorescein
55 diacetate (DCFH-DA) were purchased from Sigma-Aldrich. The singlet oxygen trapping agent 2,2,6,6-
56 tetramethyl-4-piperidine (TEMP) and the free radicals trapping agent 5,5-dimethyl-1-pyrroline *N*-
57 oxide (DMPO) were purchased commercially from TCI.

58 1.2. Instruments


59 Fluorescence and UV-vis absorption spectra were recorded using a Shimadzu RF-5301PC fluorometer
60 and an Agilent 8453 spectrophotometer, respectively. 1H and ^{13}C NMR spectra were collected on a
61 Bruker 500 MHz spectrometer. Confocal laser scanning microscope (CLSM) images were obtained
62 using an Olympus FV3000 confocal laser scanning microscope. The absorbance measurements for cell
63 studies were determined using a SpectraMax Gemini EM microplate reader (Molecular Devices, San
64 Jose, CA, USA). Electron spin resonance (EPR) experiments were performed on an ESR Spectrometer
65 (JEOL, JEX-X320).

66 2. Synthesis of thiophene-bridged heavy-atom-free BODIPY photosensitizers (PSs)

67 2.1. Overall synthetic schemes



68 **Scheme S1.** Synthesis of thiophene-conjugated donors (TPA-th, DP-Bth, and Cbz-Bth). Reagents and
 69 conditions: (i) 2-Bromothiophene, Potassium carbonate, Tetrakis(triphenylphosphine)palladium(0),
 70 THF, reflux 3 h; (ii) Butyllithium, Trimethyl borate, Hydrochloric acid. Tetrahydrofuran, -78 °C; iii)
 71 5-bromo-benzothiophene, sodium tert-butoxide, Tris(dibenzylideneacetone)dipalladium, toluene,
 72 reflux, 2 h.



74 **Scheme S2.** Synthesis of thiophene-bridged BODIPY PSs (TPA-th-BDP, DP-Bth-BDP, and Cbz-
 75 Bth-BDP). Reagents and conditions: (iv) Potassium carbonate,
 76 Tetrakis(triphenylphosphine)palladium(0). Toluene, Ethanol, Water (v/v/v = 2:2:1), reflux 3 h.

79 2.2. Detailed synthetic procedures

80 2.2.1. Synthesis of donor-thiophene units (TPA-th, DP-Bth, and Cbz-Bth)

81 TPA-B(OH)₂ was synthesized from the previously reported method.^[1]

82 TPA-th-B(OH)₂ was synthesized from the previously reported method.^[2]

83 DP-Bth was synthesized from the previously reported method.^[3]

84 Cbz-Bth was synthesized from the previously reported method.^[3]

85 DP-Bth-B(OH)₂

86 A solution of DP-Bth (1 g, 3.32 mmol) in anhydrous THF (20 mL) was cooled to -78 °C under an
87 argon atmosphere. Then, *n*-butyllithium (2.5 M in hexane, 3.65 mmol) was then slowly added dropwise
88 to the mixture. The reaction mixture was stirred for one hour at -78 °C. After stirring, trimethyl borate
89 (0.43 mL, 3.98 mmol) was added to the mixture at once, and the mixture was allowed to warm to room
90 temperature overnight. Then the reaction was quenched with 1 *N* aqueous hydrochloride acid solution,
91 and dichloromethane was used to extract the mixture. The organic layer was washed with brine,
92 combined and dried over magnesium sulfate. The solvent was removed, and the residue was
93 recrystallized using a small amounts of dichloromethane, followed by the addition of hexane to yield
94 white-yellowish powder (82% of yield). ¹H NMR (500 MHz, DMSO) δ 8.48 (s, 1H), 7.90 (d, *J* = 8.7
95 Hz, 1H), 7.80 (s, 1H), 7.52 (d, *J* = 2.0 Hz, 1H), 7.31 – 7.26 (m, 4H), 7.10 – 7.08 (m, 1H), 7.03 – 6.98
96 (m, 6H). ¹³C NMR (126 MHz, DMSO) δ 148.10, 144.48, 142.29, 138.67, 132.90, 129.94, 123.99,
97 123.93, 123.71, 123.57, 122.96, 120.08. LC-MS calcd for C₂₀H₁₆BNO₂S (M), [M+H]⁺ = 345.1, found
98 346.1

99 Cbz-Bth-B(OH)₂

100 A solution of Cbz-Bth (1 g, 3.34 mmol) in anhydrous THF (20 mL) was cooled to -78 °C under an
101 argon atmosphere. Then, *n*-butyllithium (2.5 M in hexane, 3.67 mmol) was slowly added dropwise to
102 the mixture. The reaction mixture was stirred for one hour at -78 °C. After stirring, trimethyl borate
103 (0.43 mL, 4.01 mmol) was added to the mixture in a single portion, and the reaction was allowed to
104 warm to room temperature overnight. Then the reaction was quenched with 1 *N* aqueous hydrochloric
105 solution, and the mixture was extracted with dichloromethane. The organic layer was washed with
106 brine, combined, and dried over magnesium sulfate. After solvent removal, the residue was
107 recrystallized using a small amount of dichloromethane, followed by the addition of hexane, to yield
108 a white-yellowish powder (77% of yield). ¹H NMR (500 MHz, DMSO) δ 8.27 (m, 3H), 8.16 (d, *J* =
109 1.9 Hz, 1H), 7.96 (d, *J* = 5.4 Hz, 1H), 7.58 (m, 2H), 7.43 (ddd, *J* = 18.0, 12.5, 4.5 Hz, 4H), 7.30 (m,
110 2H). ¹³C NMR (126 MHz, DMSO) δ 142.31, 142.26, 141.08, 133.72, 133.31, 126.73, 124.61, 124.30,
111 123.11, 122.70, 120.99, 120.43, 110.13. C₂₀H₁₄BNO₂S, [M+H]⁺ = 343.1, found 344.1

112 2.2.2. Synthesis of thiophene-bridged BODIPY PSs

113 Synthesis of BDP-I₂

114 BDP-I₂ was synthesized from the previously reported method.^[4]

115 Synthesis of TPA-BDP

116 TPA-BDP was synthesized from the previously reported method.^[5]

117 Synthesis of TPA-th-BDP

118 TPA-th-BDP was synthesized using the Suzuki coupling reaction. A solution of BDP-I₂ (300 mg, 0.52
119 mmol), compound **1** (452 mg, 1.56 mmol), tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.02
120 mmol), and potassium carbonate (715 mg, 5.2 mmol) in 50 mL of a degassed toluene/ethanol/water
121 mixture (2:2:1 v/v/v) was heated to reflux for 24 h under nitrogen. After cooling to room temperature
122 for 3 h, the toluene layer was separated from the aqueous layer. The organic layer was washed
123 successively with dichloromethane and dried over anhydrous magnesium sulfate. Then, the solvent
124 was evaporated under reduced pressure. The residue was purified by silica-gel column chromatography
125 (DCM: Hex = 1: 1). Finally, TPA-th-BDP was obtained as a Blue-violet solid in a 47.5% yield.

126 Synthesis of DP-Bth-BDP

127 DP-Bth-BDP was synthesized using the Suzuki coupling reaction. A solution of BDP-I₂ (300 mg, 0.52
128 mmol), compound **5** (539 mg, 1.56 mmol), tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.02
129 mmol), and potassium carbonate (715 mg, 5.2 mmol) in 50 mL of a degassed toluene/ethanol/water
130 mixture (2:2:1 v/v/v) was heated to reflux for 24 h under nitrogen. The reaction mixture was cooled to
131 room temperature for 3 h, and the toluene layer was separated from the aqueous layer. The organic
132 layer was washed successively with dichloromethane and dried over anhydrous magnesium sulfate.
133 Then, the solvent was evaporated under reduced pressure. The crude was purified by silica-gel column
134 chromatography (DCM: Hex = 1: 1). Finally, DP-Bth-BDP was obtained as a deep-violet solid in a
135 47.5% yield. ¹H NMR (500 MHz, CDCl₃) δ 7.68 (d, *J* = 8.7 Hz, 5H), 7.51 (s, 2H), 7.47 (d, *J* = 2.1 Hz,
136 2H), 7.38 (d, *J* = 1.2 Hz, 6H), 7.24 (dd, *J* = 8.5, 7.4 Hz, 9H), 7.15 – 7.14 (m, 1H), 7.13 – 7.12 (m, 1H),
137 7.10 (dd, *J* = 8.6, 1.1 Hz, 8H), 7.01 (d, *J* = 7.3 Hz, 4H), 6.90 (s, 2H), 2.65 (s, 6H), 1.43 (s, 6H). ¹³C
138 NMR (126 MHz, CDCl₃) δ 206.94, 147.98, 145.05, 141.19, 135.97, 135.39, 135.22, 135.17, 129.33,
139 129.22, 127.90, 127.65, 124.35, 123.94, 122.67, 122.59, 119.08, 77.27, 77.02, 76.76, 53.40, 31.03,
140 13.03. LC-MS calcd for C₅₉H₄₅BF₂N₄S₂, [M+H]⁺ = 922.31, found 922.84.

141 Synthesis of Cbz-Bth-BDP

142 Cbz-Bth-BDP was synthesized using the Suzuki coupling reaction. A solution of BDP-I₂ (300 mg,
143 0.52 mmol), compound **7** (535 mg, 1.56 mmol), tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.02
144 mmol), and potassium carbonate (715 mg, 5.2 mmol) in 50 mL of a degassed toluene/ethanol/water

145 mixture (2:2:1 v/v/v) was heated to reflux for 24 h under nitrogen. After the reaction, the mixture was
146 allowed to cool to room temperature over 3 h, and the toluene layer was separated from the aqueous
147 layer. The organic layer was then washed successively with dichloromethane and dried over anhydrous
148 magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified
149 by silica-gel column chromatography (DCM: Hex = 1: 1) mixture as the eluent. Finally, Cbz-Bth-BDP
150 was obtained as a magenta solid in 37% yield. ¹H NMR (500 MHz, CD₂Cl₂) δ 8.11 – 8.07 (m, 4H),
151 7.99 – 7.97 (m, 2H), 7.91 – 7.89 (m, 2H), 7.45 – 7.42 (m, 3H), 7.37 – 7.32 (m, 12H), 7.23 – 7.19 (m,
152 4H), 7.14 – 7.13 (m, 2H), 2.62 (s, 6H), 1.18 (s, 6H). ¹³C NMR (126 MHz, CD₂Cl₂) δ 147.90, 141.24,
153 132.98, 129.52, 125.95, 124.61, 123.38, 123.23, 122.22, 121.98, 121.91, 121.67, 121.25, 120.22,
154 119.87, 109.82, 53.88, 53.66, 53.44, 53.23, 53.01, 30.54, 13.66, 12.54. LC-MS calcd for
155 C₅₉H₄₁BF₂N₄S₂ [M-H]⁺, 917.2834; found, 917.20.


156

158




161





172


173 **Figure S7.** ^{13}C NMR spectrum (500 MHz) of **Cbz-Bth-B(OH)₂** in DMSO- d_6 .



174

175 **Figure S8.** ^{13}C NMR spectrum (500 MHz) of **Cbz-Bth-BDP** in DMSO- d_6 .


176




177

178 **Figure S9.** ¹³C NMR spectrum (500 MHz) of TPA-BDP in CD₂Cl₂.


179





182


183 **Figure S11.** ^{13}C NMR spectrum (500 MHz) of **DP-Bth-BDP** in CD_2Cl_2 .



184

185 **Figure S12.** ^{13}C NMR spectrum (500 MHz) of **Cbz-Bth-BDP** in CD_2Cl_2 .


186



187

188 **Figure S13.** HRMS (ESI) of DP-Bth-B(OH)₂.


189



190

191 **Figure S14.** HRMS (ESI) of Cbz-Bth-B(OH)₂.


192



193


194 **Figure S15.** HRMS (ESI) of TPA-th-BDP.

195



196

197 **Figure S16.** HRMS (ESI) of DP-Bth-BDP.



198

199 **Figure S17.** HRMS (ESI) of Cbz-Bth-BDP.

200

201

202 3. Additional experimental details and methods

203 Fluorescence Quantum Yield Measurements

204 Rhodamine 6G ($\Phi_s = 0.93$ in methanol) was used as the reference to determine the relative
205 fluorescence quantum yields of the synthesized compounds.^[6]

$$206 \quad \Phi_x = \Phi_s (F_x/F_s) (A_s/A_x) (\lambda_{exs}/\lambda_{exx}) (n_x/n_s)$$

207 where Φ represents the quantum yield; F is the integrated area under the corrected emission spectrum;
208 A stands for the absorbance at the excitation wavelength; λ_{ex} is the excitation wavelength; and the
209 subscripts x and s refer to the unknown compound and the reference, respectively. The refractive index
210 of the solvent is denoted by n. Due to the low concentrations of the solutions (10^{-6} - 10^{-7} mol/L), changes
211 in the refractive index were considered negligible. All values for relative polarity were normalized
212 from measurements of solvent shifts in absorption spectra, with data extracted from Christian
213 Reichardt, Solvents and Solvent Effects in Organic Chemistry, Wiley-VCH Publishers, 3rd ed., 2003.

214 ROS detection

215 1) DCFH Assay

216 General ROS generation was measured using 2,7-dichlorodihydrofluorescein (DCFH). Since DCFH
217 tends to self-oxidize upon prolonged storage, a more stable derivative, DCFH-DA, was acquired
218 commercially and hydrolyzed to prepare DCFH stock solutions. The protocol was as follows: 0.5 mL
219 of 1 mM DCFH-DA in ethanol stock solution was mixed with 2 mL of 10 mM NaOH aqueous solution
220 and stirred in the dark for 30 min to prepare the DCFH stock solution. When DCFH reacts with reactive
221 oxygen species, green fluorescence ($\lambda_{em} = 523$ nm) is generated. To compare ROS generation, the
222 synthesized photosensitizers were irradiated with a 530 nm PDT lamp, and the fluorescence intensity
223 of DCFH was recorded at 523 nm.

224 2) DHR123 Assay

225 DHR123 (Dihydrorhodamine 123) was used as the superoxide radical indicator in solution tests. This
226 indicator is converted to Rhodamine 123 in the presence of $O_2^{\cdot-}$. Solutions of thiophene-bridged
227 BODIPY PSs (**Cbz-Bth-BDP**, **DP-Bth-BDP**, and **TPA-th-BDP**) were prepared at a concentration of
228 5 μ M, and DHR123 was prepared at a concentration of 10 μ M in PBS 0.01 M (pH = 7.4) in 10%
229 DMSO. The cuvettes containing the test substances were exposed to a green PDT Lamp (power
230 density: 10 mW cm⁻²) for varying durations (0, 10, 20, 30...80, 90, and 100 seconds). The fluorescence
231 spectra were recorded immediately following each irradiation period.

232 3) HPF Assay

233 HPF (Hydroxylphenyl Fluorescein) was utilized as a chemical sensor specifically for hydroxyl radicals

among type I ROS. HPF is specifically oxidized by OH^\cdot and converted to strongly fluorescent fluorescein at 519.5 nm wavelength. The fluorescence intensity of HPF (10 μM) was measured upon irradiation at 530 nm with a PDT Lamp (light power intensity: 100 mW cm^{-2} , 10 s interval). Each photosensitizer's concentration was 5 μM in PBS (10 mM, pH 7.4, containing 10% DMF). Since DMSO can scavenge OH^\cdot , the HPF stock solution was prepared in DMF solvent. The fluorescence intensity ratio (F/F_0) of HPF at 519.5 nm was recorded (F_0 : each compound's fluorescence intensity of HPF without irradiation).

4) ABDA Assay

Singlet oxygen generation by thiophene-bridged BODIPY PSs (**Cbz-Bth-BDP**, **DP-Bth-BDP**, and **TPA-th-BDP**) was tested using 9,10-anthracenedipropionic acid (ABDA) as a singlet oxygen capture agent. In brief, the absorbance of ABDA at 378 nm was adjusted to approximately 1.0 in aqueous solution. Samples of BODIPY PSs (**Cbz-Bth-BDP**, **DP-Bth-BDP**, and **TPA-th-BDP**), each at a concentration of 5 μM , were added to separate cuvettes. These cuvettes were then irradiated with a 530 nm PDT lamp (power density: 100 mW cm^{-2}) for various durations (0, 20, 40, 60...140, 160, and 180 seconds). The absorption spectra were recorded immediately after each irradiation period.

5) Singlet oxygen Quantum Yield

Calculations of relative singlet oxygen quantum yields were conducted based on previous literature. I_2 -BDP ($\Phi_\Delta = 0.85$ in toluene) served as the standard for determining the relative singlet oxygen quantum yields of synthesized compounds.

A solution of 1,3-Diphenylisobenzofuran (DPBF, singlet oxygen trap) and the synthesized photosensitizers was added to a cuvette filled with air-saturated toluene. The solutions were kept in the dark until the absorbance readings stabilized, followed by continuous light irradiation. The absorption of DPBF at 414 nm was monitored every 3 seconds to obtain the decay rate of the photosensitizing processes. Measurements were performed using a green LED light source (10 mW cm^{-2}).

The $^1\text{O}_2$ quantum yields of the synthesized compounds were calculated using the equation.

$$\phi_\Delta(\text{PS}) = \phi_\Delta(\text{ref}) \times \frac{m(\text{PS})}{m(\text{ref})} \times \frac{F(\text{ref})}{F(\text{PS})} \times \frac{m(\text{PS})}{m(\text{ref})}$$

where PS and ref represent the photosensitizer and the reference (I_2 -BDP), respectively. m denotes the slope of the change in absorbance of DPBF at its absorbance maxima over irradiation time. F is defined as $F = 1 - 10^{-\text{OD}}$, where OD represents the optical density at the excitation wavelength. PF represents absorbed photonic flux ($\mu\text{Einstein dm}^{-3}\text{s}^{-1}$).

Electro Paramagnetic Resonance (EPR) Analysis

266 EPR spectrum was detected using 5,5-dimethyl-1-pyrroline *N*-oxide (DMPO) as a superoxide radical
267 spin trapping agent, 5-tert-Butoxycarbonyl-5-methyl-1-pyrroline-*N*-oxide (BMPO) as a hydroxyl
268 radical spin trapping agent, and 2,2,6,6-tetramethylpiperidine (TEMP) as a singlet oxygen spin
269 trapping agent. The samples were prepared in 4 mL vials. All tests were conducted at 293 K with the
270 following settings: Frequency = 9432.830 MHz; MOD Frequency = 100.00 kHz; Power = 3.0 mW.

271 1) Superoxide radical spin trapping experiment. Solutions of BODIPY PSs (TPA-BDP, **TPA-th-BDP**,
272 **DP-Bth-BDP**, and **Cbz-Bth-BDP**) were prepared at a concentration of 200 μM in DMF. TEMP (50
273 $\mu\text{L mL}^{-1}$) was added to each solution in a 4 mL vial. The samples were irradiated using a 530 nm PDT
274 lamp (power density: 100 mW cm^{-2}) for 3 min. EPR signals were measured immediately after
275 photoradiation.

276 2) For hydroxyl radical detection, BODIPY PSs (TPA-BDP, **TPA-th-BDP**, **DP-Bth-BDP**, and **Cbz-**
277 **Bth-BDP**) were prepared at a concentration of 200 μM in THF. BMPO (50 $\mu\text{L mL}^{-1}$) was added to
278 each solution in a 4 mL vial, followed by irradiation with a 530 nm PDT lamp (power density: 100
279 mW cm^{-2}) for 3 min. BMPO, FeCl_2 , and H_2O_2 stocks were all prepared in deionized water (DW). PSs
280 were prepared in THF. Standard Fenton reaction conditions were set up using FeCl_2 (1 mM, 1 eq) and
281 H_2O_2 (10 mM, 1 eq) to validate hydroxyl radical generation.

282 3) For singlet oxygen detection, solutions of BODIPY PSs (TPA-BDP, **TPA-th-BDP**, **DP-Bth-BDP**,
283 and **Cbz-Bth-BDP**) (200 μM in DMF), were prepared with the addition of DMPO (50 $\mu\text{L mL}^{-1}$) in 4
284 mL vials. The samples were exposed to a 530 nm PDT lamp (power density: 100 mW cm^{-2}) for 3 min.

285 Cyclic Voltammogram

286 Cyclic voltammetry was used to examine the electrochemical properties of the synthesized heavy-
287 atom-free BODIPY PSs. Measurements were performed using a potentiostat (eDAQ, EA161) at a scan
288 rate of 100 mV s^{-1} . Cyclic voltammetry data was obtained using ferrocene as a reference to measure
289 the oxidation and reduction potentials of the synthesized heavy-atom-free BODIPY PSs (TPA-BDP,
290 **TPA-th-BDP**, **DP-Bth-BDP**, and **Cbz-Bth-BDP**). Ferrocene was used as a reference in anhydrous
291 dichloromethane with tetrabutylammonium hexafluorophosphate (0.1 M). The working electrode was
292 prepared by drop-casting the sample onto a platinum (Pt) plate, while a Pt/Ti wire anode served as the
293 counter electrode. A 3M NaCl solution was used as the reference electrode. Tetrabutylammonium
294 hexafluorophosphate (NBu_4PF_6 , 0.10 M) in distilled dichloromethane was used as the electrolyte
295 solution. The energy gap between the highest occupied molecular orbital (HOMO) and lowest
296 unoccupied molecular orbital (LUMO) levels was determined by measuring the onset oxidation
297 potentials ($E_{\text{OX onset}}$). The LUMO and HOMO energy levels were determined using the following
298 equations:

$$299 \quad \text{LUMO} = - (4.8 + E_{\text{Red}} - E_{\text{FC}}) \quad (E_{\text{FC}}: \text{ferrocene's } E_{\text{OX}}^{\text{onset}})$$

$$300 \quad \text{HOMO} = - (4.8 + E_{\text{ox}} - E_{\text{FC}})$$

UV optical band (band gap) = LUMO – HOMO

Computational Method

Quantum calculations for this study were performed using Gaussian 16. The Avogadro software was used to visualize molecular orbitals.^[7] All calculations were performed at the M062X/def2-SVP level of theory with the SMD solvation model in a polar environment (water),^[8] unless mentioned otherwise. The corrected linear solvation formalism was used to obtain the electronic energy of various excited states.

Given the limitations of the M062X functional in accurately describing the S_1 (ET) state, the B3LYP/def2-SVP level of theory was utilized for the geometry optimization of the S_1 (ET) state under the linear solvation formalism. To ensure complete charge separation during these calculations, two dihedral angles of the 6-position substituents were constrained to 90°. Following geometry optimization, the M062X/def2-SVP level of theory with the corrected linear solvation formalism was applied to calculate the electronic energy of the S_1 (ET) state.

The ΔE_{ST} values were calculated based on the difference between the S_1 and T_n ($n=1,2$) energy levels. Spin-orbit coupling (SOC) values were calculated using ORCA 5.0 [9] based on the optimized S_1 (ET) molecular structure, employing the M06-2X/def2-SVP level of theory alongside the linear solvation formalism.

The ionization potential (IP) and electron affinity (EA) of various substituents were calculated by first optimizing the geometries of the neutral molecules, followed by the corresponding radicals (cations for IP and anions for EA). The IP and EA values were then determined based on the Gibbs energy difference between the optimized radical and neutral species.

The electron affinity (EA) of the photosensitizers in the triplet state (T_1) was calculated through a multi-step process. First, the triplet state geometries were optimized using time-dependent density functional theory (TD-DFT). Subsequently, energy correction was applied using the corrected linear solvation formalism. Next, the corresponding anion was optimized. Finally, the EA values were determined based on the electronic energy difference between the optimized radical and neutral T_1 species.

Bio studies

1) Cell Culture

Human breast cancer cell lines MDA-MB-231, T47D, and MCF-7 were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (GIBCO), supplemented with 10% fetal bovine serum (HyClone), 100 U mL⁻¹ penicillin, and 100 µg mL⁻¹ streptomycin (HyClone). The cells were cultured in a humidified incubator (5% CO₂ at 37°C).

334 2) Cell Viability Assay

335 The cytotoxic effects of BODIPY PSs (TPA-BDP, **TPA-th-BDP**, **DP-Bth-BDP**, and **Cbz-Bth-BDP**)
336 on MDA-MB-231 cells were determined using an Thiazolyl Blue tetrazolium bromide, 98% (MTT)-
337 based cell viability assay kit. Briefly, ca. 8×10^3 MDA-MB-231 cells per well were seeded in a 96-
338 well plate for 24 h at 37 °C in a humidified, 5% CO₂ atmosphere. The cells were then treated with
339 different concentrations of Cbz-Bth-BDP (0, 0.5, 1, 2, 4, and 8 μ M) to determine the IC₅₀ value. 24 h
340 later, the cells were subjected to photoirradiation (530 nm PDT Lamp, 10 min, 100 mW cm⁻²).
341 Following another day of incubation, 10 μ L of MTT (5 mg mL⁻¹) was added to each well, and the cells
342 were incubated for an additional 2–4 h. The medium was suctioned, and 150 μ L of DMSO was added
343 to dissolve the formazan crystals. Cell viability was determined using a multiplate reader (HOIL
344 BIOMED Co.) by recording the absorbance at 570 nm. Cell viability was calculated using the
345 following equation:

346
$$\text{Cell viability (\%)} = (\text{OD}_{ps} - \text{OD}_{\text{blank control}}) / (\text{OD}_{\text{control}} - \text{OD}_{\text{blank control}}) \times 100\%$$

347 3) Intracellular NADH Detection

348 The effect of BODIPY PSs (TPA-BDP, **TPA-th-BDP**, **DP-Bth-BDP**, and **Cbz-Bth-BDP**) on
349 intracellular NADH levels was evaluated using the NAD⁺/NADH-Glo™ Assay (bioluminescent) kit.
350 In brief, MDA-MB-231 cells were seeded in a 96-well plate at a density of 1×10^4 per well and cultured
351 in a cell incubator at 37 °C. The cells were treated with the indicated drugs for 24 h, then the initial
352 medium was discarded and replaced with 50 μ L PBS. Following 530 nm photoirradiation for 10 min
353 at a density of 100 mW cm⁻², the luminescence of the samples was measured according to the
354 instructions of the manufacturer. The NAD⁺/NADH ratios were calculated by dividing the
355 luminescence of the NAD⁺ samples by the luminescence of the NADH samples:

356
$$\text{Ratio of NAD}^+/\text{NADH} = ((\text{Luminescence of NAD samples})) / (\text{luminescence of NADH samples})$$

357 4) Western blot analysis

358 The expression of pyroptosis-associated proteins, including cleaved-caspase3, caspase3, and GSDME,
359 was evaluated using western blot. After the treatment with BODIPY PSs (TPA-BDP, **TPA-th-BDP**,
360 **DP-Bth-BDP**, and **Cbz-Bth-BDP**), the samples were harvested and washed with cold PBS. Cell
361 lysates were prepared by incubating the cells in ice-cold radioimmunoprecipitation assay buffer,
362 followed by sonication and centrifugation (20,000 g, 10 min). Protein concentrations were determined
363 using a bicinchoninic acid (BCA) assay. 30-50 micrograms of total protein samples were separated by
364 SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% w/v skim
365 milk and incubated overnight at 4 °C with primary antibody: GSDME (Abcam, catalog no. ab215191),
366 cleaved-caspase3 antibody (Cell Signaling Technology, catalog no. 9661s), IL-1 β (GeneTex, catalog
367 no. GTX74034) and β -actin (Santa Cruz Biotechnology, catalog no. sc-47778) at a 1:1,000 dilution.

368 After washing with PBST, the membranes were incubated for 2 h with the relevant secondary antibody
369 at a 1:1,000 dilution: anti-mouse (GeneTex, catalog no. GTX213110-01); anti-rabbit (Santa Cruz
370 Biotechnology, catalog no. sc-2357). The protein expression levels were detected using enhanced
371 chemiluminescence reagents (Luminate, Merck Millipore) and imaged using a Syngene Bio Imager
372 (Synoptics Ltd., Cambridge, UK).

373 **5) LDH Release Measurement**

374 The release of LDH (lactose dehydrogenase) was measured using the CytoTox96™ Non-Radioactive
375 Cytotoxicity Assay Kit (Promega, USA). For the positive control, maximum LDH release was induced
376 by treating cells with a lysis buffer, followed by incubation at 37°C and 5% CO₂ for 45 min. The
377 substrate solution, stored at -20°C, was warmed to room temperature before use. The substrate was
378 added to the medium of each group and incubated in the dark for 30 min. A stop solution was then
379 added to each well. The proportion of LDH released was calculated using the following formula: LDH
380 Release (%) = (LDH treated average value - LDH untreated cells average value) / (LDH total lysis
381 average value - LDH untreated cells average value) × 100. Absorbance was measured at 490 nm using
382 a multi-plate reader (HOIL BIOMED Co.)

383 **6) ATP Release Measurement**

384 ATP release into the cell medium was determined to evaluate cell membrane damage. Cells were
385 treated with the indicated drugs for 24 h, the medium was replaced with fresh medium, and the cells
386 were exposed to photoirradiation (530 nm, 100 mW cm⁻², 10 min). After a further 6 h of incubation,
387 the medium was collected and the ATP concentration was measured using a multi-plate reader.

388 **7) 3D tumor spheroid inhibition**

389 For 3D multicellular spheroids (MCSs), approximately 2 × 10³ T47D cells per well were seeded in 96-
390 well plates (U-shaped) (Sumitomo Bakelite, Japan). After 3 days of incubation, the T47D MCSs were
391 treated with thiophene-bridged BODIPY PSs (**TPA-th-BDP**, **DP-Bth-BDP**, and **Cbz-Bth-BDP**) for
392 48 h and exposed to photoirradiation (530 nm, 100 mW cm⁻², 20 min). After culturing for another 48
393 h, the viability of the spheroid was determined using the CellTiter-Glo™ 3D Cell Viability Assay
394 (Promega, Germany). The luminescence of ATP was detected through a multi-plate reader.

395 **8) Live/Dead tumor spheroid Imaging**

396 The anticancer effects of BODIPY PSs (**TPA-BDP**, **TPA-th-BDP**, **DP-Bth-BDP**, and **Cbz-Bth-BDP**)
397 on tumor spheroids were determined using Calcein-AM/propidium iodide (PI) co-stain assay. In brief,
398 after treatment with the indicated drugs, the spheroid samples were stained with Calcein-AM and PI
399 in a cell incubator for 30 min. Following the washing with PBS, the stained spheroids were imaged
400 using an Olympus FV3000 confocal laser scanning microscope.

401

402 9) Cell Morphology Imaging


403 Cellular photon-induced pyroptosis was detected by FITC-Annexin V/Hoechst 33342 staining.
404 MDA-MB-231 cells were seeded in a 35 mm glass-bottom confocal dish and incubated for 24 h. The
405 cells were treated with 2 μ M of each BODIPY PSs (TPA-BDP, **TPA-th-BDP**, **DP-Bth-BDP**, and
406 **Cbz-Bth-BDP**) and incubated for another 24 h. Morphological changes were visualized using
407 fluorescence microscopy with excitation wavelengths of 405 nm and 640 nm. Emission was collected
408 from 410 to 470 nm (blue channel) and 650 to 750 nm (red channel). For the Annexin V/Hoechst
409 33342 staining, 10X binding buffer was diluted into 1X binding buffer using distilled water. The
410 working solution of 1 μ g mL⁻¹ of Hoechst 33342 was then prepared in 1X binding buffer. Cells were
411 stained with a mixture of Hoechst 33342 and FITC-Annexin V after washing with binding buffer.
412 Confocal images were captured using excitation of 405 and 488 nm, with emission signals collected
413 at 430 to 470 nm (blue channel) and 500 to 540 nm (green channel).

414 10) Calcein/AM staining

415 To evaluate the effects of heavy-atom-free BODIPY PSs (TPA-BDP, **TPA-th-BDP**, **DP-Bth-BDP**,
416 and **Cbz-Bth-BDP**) on MDA-MB-231 cells, ca. 3×10^4 MDA-MB-231 cells were seeded in glass
417 bottom confocal dishes and cultured overnight. The cells were then incubated with 2 μ M concentration
418 of each BODIPY PSs (TPA-BDP, **TPA-th-BDP**, **DP-Bth-BDP**, and **Cbz-Bth-BDP**) for another 24
419 h. After exposure to 530 nm light (100 mW cm⁻²) for 10 min, photo-irradiated cells were incubated for
420 24 h in the incubator (37 °C, 5% CO₂). They were then stained with 2 μ M Calcein AM (Calcein
421 acetoxymethyl ester, live cell marker, λ_{ex} = 473 nm and λ_{em} = 490-590 nm) and 4 μ M PI (propidium
422 iodide, dead cell marker, λ_{ex} = 559 nm and λ_{em} = 575-675 nm) for 30 min. After rinsing with PBS,
423 cell imaging was carried out using an Olympus FV3000 confocal laser scanning microscope.

424 11) Statistical analyses


425 Data were analyzed by one-way analysis of variance using SPSS (version 21.0; IBM Corp., Armonk,
426 NY, USA). Tukey's post hoc test was used to determine the significance of all pairwise comparisons
427 of interest. Statistical significance was defined as * P < 0.05.



428

429 **Figure S18.** Photophysical properties of **TPA-th-BDP**. (A) Absorbance spectra and (B) Fluorescence
 430 spectra of **TPA-th-BDP** in different organic solvents (PBS, DCM, THF, DMF, Toluene, EtOH, and
 431 Acetonitrile). The concentration of **TPA-th-BDP** was maintained at 5 μ M. Fluorescence spectra were
 432 obtained upon excitation at the maximum excitation wavelength for each solvent.


433



434

435 **Figure S19.** Photophysical properties of **DP-Bth-BDP**. (A) Absorbance spectra and (B) Fluorescence
 436 spectra of **DP-Bth-BDP** in different organic solvents (PBS, DCM, THF, DMF, Toluene, EtOH, and
 437 Acetonitrile). The concentration of **DP-Bth-BDP** was maintained at 5 μ M. Fluorescence spectra were
 438 obtained upon excitation at the maximum excitation wavelength for each solvent.


439



440

441 **Figure S20.** Photophysical properties of **Cbz-Bth-BDP**. (A) Absorbance spectra and (B) Fluorescence
 442 spectra of **Cbz-Bth-BDP** in different organic solvents (PBS, DCM, THF, DMF, Toluene, EtOH, and
 443 Acetonitrile). The concentration of **Cbz-Bth-BDP** was maintained at 5 μM . Fluorescence spectra were
 444 obtained upon excitation at the maximum excitation wavelength for each solvent.


445



446

447 **Figure S21.** Determination of molar extinction coefficient (ϵ) for BODIPY PSs (**TPA-th-BDP**, **DP-**
 448 **Bth-BDP**, and **Cbz-Bth-BDP**) in THF (A-C) and PBS (D-F). UV-Vis absorption spectra of BODIPY
 449 derivatives were measured in THF and PBS at room temperature (25°C). The spectra were recorded at
 450 various concentrations ranging from 0.25 to 10 μM . Calibration curve of absorbance at the λ_{max} (nm)
 451 against the concentration of the compounds. The molar extinction coefficient (ϵ) was calculated from
 452 the slope of the linear regression, expressed as ϵ ($\text{L} \cdot \text{mol}^{-1} \cdot \text{cm}^{-1}$).


453



454

455 **Figure S22.** Ionization potential (IP) of various substituents in water and toluene. A lower IP value
 456 indicates a stronger electron-donating ability.


457



458

459 **Figure S23.** Fluorescence intensity of thiophene-bridged BODIPY PSs (TPA-th-BDP, DP-Bth-BDP,
 460 and Cbz-Bth-BDP). The fluorescence intensity ratio (F/F_0) was measured in different fractions of THF
 461 and H₂O. F and F_0 are the fluorescence intensities of BODIPY PCs in the absence and presence of
 462 THF, respectively).


463



464

465 **Figure S24.** (A) DCFH assays for ROS generation. The fluorescence intensity of DCFH (10 μM) was
 466 monitored at 523 nm upon irradiation with a 530 nm PDT Lamp (light intensity of 10 mW cm^{-2}) at 5
 467 s intervals. Each photosensitizer was prepared at a concentration of 5 μM in PBS solution (10 mM, pH
 468 7.4, containing 10% DMSO). The fluorescence intensity ratio (F/F_0) of DCFH at 525 nm was recorded
 469 (F_0 : each compound's fluorescence intensity of DCFH at 0 s). Fluorescence spectra are shown for (B)
 470 DCFH only, (C) BDP-I₂, (D) BDP-Br₂, (E) **Cbz-Bth-BDP**, (F) **DP-Bth-BDP**, and (G) **TPA-th-BDP**.


471



472

473 **Figure S25.** (A) DHR123 assays for superoxide radicals ($\text{O}_2^{\bullet-}$) generation. The fluorescence intensity
 474 of DHR123 (10 μM) was measured at 528 nm upon irradiation with a 530 nm PDT Lamp (100 mW
 475 cm^{-2}) at 20 s intervals. Each photosensitizer (5 μM) was prepared in PBS solution (10 mM, pH 7.4)
 476 containing 10% DMSO. The fluorescence intensity ratio (F/F_0) of DHR123 at 528 nm was recorded
 477 (F_0 : each compound's fluorescence intensity of DHR123 at 0 s). Fluorescence spectra are shown for
 478 (B) DHR123 only, (C) BDP-I₂, (D) BDP-Br₂, (E) **Cbz-Bth-BDP**, (F) **DP-Bth-BDP**, (G) **TPA-th-**
 479 **BDP**, and (H) **TPA-BDP**.


480



481


482 **Figure S26.** (A) HPF assays for hydroxyl radicals ($\bullet\text{OH}$) generation. The fluorescence intensity of
 483 HPF ($10\ \mu\text{M}$) was measured at 528 nm upon irradiation with a 530 nm PDT Lamp ($100\ \text{mW cm}^{-2}$) at
 484 10 s intervals. Each photosensitizer ($5\ \mu\text{M}$) was prepared in PBS buffer (10 mM, pH 7.4) containing
 485 10% DMSO. The fluorescence intensity ratio (F/F_0) of HPF at 528 nm was recorded (F_0 : each
 486 compound's fluorescence intensity of HPF at 0 s). Fluorescence spectra are shown for (B) Comparison
 487 of singlet oxygen generation by BODIPY-based photosensitizers, (C) BDP- I_2 , (D) BDP- Br_2 , (E) **Cbz-**
 488 **Bth-BDP**, (F) **DP-Bth-BDP**, (G) **TPA-th-BDP**, and (H) TPA-BDP.

489



490


491 **Figure S27.** ABDA assay for singlet oxygen ($^1\text{O}_2$) generation. The fluorescence intensity of DHR123
 492 ($10\ \mu\text{M}$) was measured at 528 nm upon irradiation with a 530 nm PDT Lamp ($100\ \text{mW cm}^{-2}$) at 10 s
 493 intervals. Each photosensitizer ($5\ \mu\text{M}$) was prepared in PBS buffer (10 mM, pH 7.4) containing 10%
 494 DMSO. (A) The absorbance ratio (A/A_0) of ABDA at 378 nm was recorded (A_0 : each compound's
 495 absorbance of ABDA at 0 s). Absorbance spectra are shown for (B) Comparison of singlet oxygen
 496 generation by BODIPY PCs, (C) BDP- I_2 , (D) BDP- Br_2 , (E) **Cbz-Bth-BDP**, (F) **DP-Bth-BDP**, (G)
 497 **TPA-th-BDP**, and (H) TPA-BDP.



498

499 **Figure S28.** EPR spectra of (A) DMPO (superoxide radical trap, $50 \mu\text{L mL}^{-1}$), (B) BMPO (hydroxyl
500 radical trap, $50 \mu\text{L mL}^{-1}$), and (C) TEMP (singlet oxygen trap, $50 \mu\text{L mL}^{-1}$) were used to assess ROS
501 generation by photo-irradiated thiophene-bridged BODIPY-based photosensitizers. Experiments were
502 performed in DMF, ACN, and DW solutions, respectively. Conditions: 530 nm green light; power
503 density: 100 mW cm^{-2} ; irradiation time: 3 min. The concentration of radical trapping agents: $200 \mu\text{M}$.
504

505



506

507 **Figure S29.** ROS assays in aqueous solutions with varying fractions of THF to investigate the role of
508 aggregation. (A) Degradation rates of DPBF by photoexcited **CBz-Bth-BDP** in THF/water solvent
509 systems. A_0 and A are the absorbance of DPBF at 417 nm before and after irradiation, respectively.
510 (B) DHR123 assays in THF/water mixture by photoexcited **CBz-Bth-BDP**. The fluorescence intensity
511 of DHR123 ($10 \mu\text{M}$) was measured upon irradiation with a 530 nm PDT Lamp (100 mW cm^{-2}) at 20
512 s intervals. The fluorescence intensity ratio (F/F_0) of DHR123 at 530 nm was recorded (F_0 : each
513 compound's fluorescence intensity of DHR123 at 0 s).

514




Figure S30. Photostability tests of BODIPY PSs (5 uM) in DCM solution under light irradiation (Irradiation time: 1 min interval, irradiation condition: 530 nm PDT Lamp, 100 mW cm⁻²). Photostability was detected by using a UV-Vis spectrometer. Absorbance changes of (A) **Cbz-Bth-BDP**, (B) **DP-Bth-BDP**, (C) **TPA-th-BDP**, and (D) Rose Bengal (RB).




Figure S31. Optimized ground state geometries of **TPA-th-BDP**, **DP-Bth-BDP**, and **Cbz-Bth-BDP** in water, with the dihedral angles of the 2 and 6-substituents highlighted in the insets.




Figure S32. Frontier molecular orbitals (FMO) and their energy levels for (A) **Cbz-Bth-BDP**, (B) **DP-Bth-BDP**, and (C) **TPA-th-BDP**, based on the optimized ground state geometries in water. Note that the plotted energy levels are not to scale for clarity.




Figure S35. Cyclic voltammetry (CV) measurements of **DP-Bth-BDP** (left) and **TPA-th-BDP** (right).






Figure S36. Comparison of **BODIPY**-based photosensitizers-mediated cyt *c* photoreduction efficiency. The appearance of new spectral peaks at the β band (520 nm) and the α band (550 nm) — two characteristic spectroscopic signatures of reduced Cyt *c* (Fe^{2+}) — indicates the photoreduction of Cyt *c* (Fe^{3+}) to (Fe^{2+}). (A-D) Absorbance spectra of cyt *c* upon photoirradiation with (A) **Cbz-Bth-BDP**, (B) **DP-Bth-BDP**, (C) **TAP-th-BDP**, and (D) **TPA-BDP** in aerobic conditions (Air). (E) Absorbance spectra of cyt *c* after photoirradiation with **Cbz-Bth-BDP** in nitrogen (N_2) under green light. All photosensitizers were used at a concentration of $2\text{ }\mu\text{M}$, with NADH at $40\text{ }\mu\text{M}$, and cyt *c* at $10\text{ }\mu\text{M}$ in aerobic PBS solution. (F) Total comparison of BODIPY PSs-mediated Cyt *c* photoreduction efficiency.



558

559 **Figure S37.** Photocatalytic reduction of Cyt *c* (Fe^{3+}) in the presence and absence of NADH.



560


561 **Figure S38.** Photocatalytic reduction of Cyt *c* (Fe^{3+}) in (A) the absence or (B) the presence of NAD
562 radical trapping reagent (CYPMPO).

	TON	TOF (min^{-1})
Hypoxia	2.931	0.5862
Normoxia	2.2675	0.4535

563

564 **Figure S39.** Calculation of TON and TOF


565



566


567 **Figure S40.** (a) Comparison of cell viability at three different time points (5, 10, and 15 min) after
 568 treatment with **Cbz-Bth-BDP** at various concentrations (0, 0.5, 1, 2, 4, and 8 μ M) and followed by
 569 photo-irradiation. Light power density: 100 mW cm^{-2} , irradiation time: 10 min. Bar graphs represent
 570 the mean cell viability from MTT assays, with error bars indicating standard deviation (SD) values (n
 571 = 3). * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.

572




573

574 **Figure S41.** Formazan formation assay in MDA-MB-231 cells with or without light irradiation. MDA-
 575 MB-231 cells were treated with 2 μ M of indicated concentrations of heavy-atom-free BODIPY PSs
 576 (TPA-BDP, **TPA-th-BDP**, **DP-Bth-BDP**, and **Cbz-Bth-BDP**). The formation of formazan was
 577 detected using an MTT assay. Three independent experimental runs yielded comparable findings.
 578 Scale bar: 50 μ m.



579


580 **Figure S42.** Confocal laser microscopy images showing the pyroptotic morphology changes in MDA-
 581 MB-231 cells. The cell membrane is stained with FITC-Annexin-V (green), and the nucleus is stained
 582 with Hoechst 33342 (blue). Scale bar: 20 μ m.



583


584 **Figure S43.** Western blot analysis of pyroptosis-related protein expression levels in MDA-MB-231
 585 cells treated with BODIPY PSs and light irradiation (530 nm, 100 mW cm⁻², 10 min). (A) Protein
 586 expression of cleaved Caspase-3 (active form of caspase 3). (B) Protein expression of GSDME-N (N-
 587 terminal fragment of gasdermin E, GSDME). (C) Protein expression of β -actin.

588



589

590 **Figure S44.** Confocal imaging of live/dead cells in MDA-MB-231 cells. Cells were treated with $2 \mu\text{M}$
 591 heavy-atom-free BODIP PSs (TPA-BDP, TPA-th-BDP, DP-Bth-BDP, and Cbz-Bth-BDP) with or
 592 without light irradiation. Live cells were stained in green by Calcein AM (green, $\lambda_{\text{ex}} = 473 \text{ nm}$ and
 593 $\lambda_{\text{em}} = 490\text{-}590 \text{ nm}$), and dead cells were stained with propidium iodide (PI) (red, $\lambda_{\text{ex}} = 559 \text{ nm}$ and λ_{em}
 594 $= 575\text{-}675 \text{ nm}$). Scale bars: $50 \mu\text{m}$.



595

596 **Figure S45.** Western blot assay showing pyroptosis-related protein expression after scavenging ROS
 597 (N-Acetyl-L-cysteine, NAC) with Cbz-Bth-BDP treatment. (A) Protein expression of cleaved
 598 Caspase-3 (active form of caspase 3). (B) Protein expression of GSDME-N (N-terminal fragment of
 599 gasdermin E, GSDME) was analyzed, after which the membrane was stripped and reprobed for β -actin
 600 (C). Light irradiation condition: 530 nm , 100 mW cm^{-2} , 10 min .

601

603 **Supplementary Reference**

- 604 [1] J. Wei, Y. Ma, C. Liu, J. Li, J. Shen, K. Y. Zhang, S. Liu, Q. Zhao, *J. Mater. Chem. C* **2021**, 9,
605 5945–5951.
- 606 [2] I. Partanen, A. Belyaev, B. Su, Z. Liu, J. J. Saarinen, I. Ibni Hashim, A. Steffen, P. Chou, C.
607 Romero-Nieto, I. O. Koshevoy, *Chem. Eur. J.* **2023**, 29, e202301073.
- 608 [3] F.-Z. Xu, L. Zhu, H.-H. Han, J.-W. Zou, Y. Zang, J. Li, T. D. James, X.-P. He, C.-Y. Wang,
609 *Chem. Sci.* **2022**, 13, 9373–9380.
- 610 [4] Y. Peng, G. Guo, S. Guo, L. Kong, T. Lu, Z. Zhang, *Angew. Chem. Int. Ed.* **2021**, 60, 22062–
611 22069.
- 612 [5] V. Nguyen, Y. Yim, S. Kim, B. Ryu, K. M. K. Swamy, G. Kim, N. Kwon, C. Kim, S. Park, J.
613 Yoon, *Angew. Chem. Int. Ed.* **2020**, 59, 8957–8962.
- 614 [6] K. Teng, W. Chen, L. Niu, W. Fang, G. Cui, Q. Yang, *Angew. Chem. Int. Ed.* **2021**, 60, 19912–
615 19920.
- 616 [7] M. D. Hanwell, D. E. Curtis, D. C. Lonie, T. Vandermeersch, E. Zurek, G. R. Hutchison, *J.*
617 *Cheminform.* **2012**, 4, 17.
- 618 [8] A. V. Marenich, C. J. Cramer, D. G. Truhlar, *J. Phys. Chem. B* **2009**, 113, 6378–6396.
- 619 [9] F. Neese, *WIREs: Comput. Mol. Sci.* **2022**, 12, e1606.

620